BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3723170)

  • 21. [Serum levels of CA 125, CA 19-9, TPA, CEA and CA 50: useful evaluation parameters in the diagnosis of ovarian cancer].
    Gadducci A; Ferdeghini M; Bartolini T; Facchini V; Bianchi R; Fioretti P
    Ann Ostet Ginecol Med Perinat; 1986; 107(4):193-9. PubMed ID: 3467641
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical usefulness of monoclonal antibody, CA 125 and CA 19-9 in ovarian cancer].
    Saitoh S; Nakanishi A; Noda T; Ando Y; Katakami Y; Kiyozuka Y; Moriyama I; Ichijo M
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2327-35. PubMed ID: 6598184
    [No Abstract]   [Full Text] [Related]  

  • 23. A monoclonal antibody radioimmunoassay for an antigenic determinant CA125 in ovarian cancer patients.
    Lian LJ; Hu XF; Liu WS; Wu AJ
    Chin Med J (Engl); 1986 Sep; 99(9):721-6. PubMed ID: 2433106
    [No Abstract]   [Full Text] [Related]  

  • 24. [Significance of a new tumor marker for breast carcinoma and ovarian carcinoma].
    Hoffmann L
    Dtsch Med Wochenschr; 1987 May; 112(21):847-9. PubMed ID: 3472869
    [No Abstract]   [Full Text] [Related]  

  • 25. [Tumor markers in epithelial carcinoma of the ovary].
    Cottini M; Carnino F; Iskra L; Rapisarda V; Mossetti C
    Minerva Ginecol; 1986 Jun; 38(6):479-84. PubMed ID: 3461313
    [No Abstract]   [Full Text] [Related]  

  • 26. Initial immunochemical characterization of MX35 ovarian cancer antigen.
    Welshinger M; Yin BW; Lloyd KO
    Gynecol Oncol; 1997 Nov; 67(2):188-92. PubMed ID: 9367706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Radioimmunological determination of cancerocerebral antigen in the blood serum of patients with ovarian tumors].
    Griaznova IM; Borisenko SA; Sokolov AV; Prokopenko PG; Makarov OV
    Akush Ginekol (Mosk); 1984 Apr; (4):27-9. PubMed ID: 6204548
    [No Abstract]   [Full Text] [Related]  

  • 28. Clinical correlations of ovarian cancer antigen NB/70K: a preliminary report.
    Dembo AJ; Chang PL; Urbach GI
    Obstet Gynecol; 1985 May; 65(5):710-4. PubMed ID: 3856794
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Immunology of malignant ovarian tumors. I. Familial occurrence, antigens and specific immunity].
    Markowska J
    Ginekol Pol; 1984 Sep; 55(9):695-700. PubMed ID: 6398791
    [No Abstract]   [Full Text] [Related]  

  • 30. [A monoclonal antibody RIA as an antigenic determinant (CA 125) in ovarian cancer patients].
    Lian LJ
    Zhonghua Fu Chan Ke Za Zhi; 1985 Sep; 20(5):257-60, 317. PubMed ID: 2417787
    [No Abstract]   [Full Text] [Related]  

  • 31. [Significance of CA 125 antigen levels in patients with ovarian cancer].
    Shimizu Y; Fujiwara H; Akagaki E; Hirota K; Kono M; Irie T; Miura S; Okudaira Y
    Gan To Kagaku Ryoho; 1986 Jan; 13(1):46-52. PubMed ID: 3455806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
    Kuzuya K; Nozaki M; Chihara T
    Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor-associated antigen(s) from granulosa cell carcinomas of the ovary.
    Bhattacharya M; Barlow JJ; Chu TM; Piver MS
    Cancer Res; 1974 Apr; 34(4):818-22. PubMed ID: 4205513
    [No Abstract]   [Full Text] [Related]  

  • 34. [Possibilities and limitations of the clinical use of specific monoclonal antibodies for epithelial ovarian carcinomas: CA125K].
    Pozzi V; D'Onofrio T; Cappa F; Mascaretti G; Meggiorini ML; Nusiner MP; Danese M
    Minerva Ginecol; 1985 May; 37(5):253-7. PubMed ID: 3861960
    [No Abstract]   [Full Text] [Related]  

  • 35. Ovarian tumor antigens.
    Benson MD; Lurain JR; Newton M
    J Reprod Med; 1983 Jan; 28(1):17-23. PubMed ID: 6187917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Distribution of one of the ascitic fluid antigens of ovarian cancer patients in malignant tumors of the stomach and intestines].
    Sergeeva NS; Vasil'ev MIu; Kovalenko TI; Sokolova NV; Avdeev GI
    Eksp Onkol; 1989; 11(2):35-7. PubMed ID: 2661204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CA-125: An evaluation.
    Nuss R; Swor MG; Benrubi MD
    J Fla Med Assoc; 1987 May; 74(5):329-32. PubMed ID: 2440975
    [No Abstract]   [Full Text] [Related]  

  • 38. Radioimmunoassay of the CA 12 5 antigen in ovarian carcinomas: advantages compared with CA 19-9 and CEA.
    Ricolleau G; Chatal JF; Fumoleau P; Kremer M; Douillard JY; Curtet C
    Tumour Biol; 1984; 5(3-4):151-9. PubMed ID: 6594738
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-specificity of the tumour marker CA 19-9: a case of ovarian carcinoma with recurrent venous thrombosis.
    Smellie S; Lambert M
    Acta Gastroenterol Belg; 1987; 50(2):241-2. PubMed ID: 3481507
    [No Abstract]   [Full Text] [Related]  

  • 40. [Distribution and diagnostic role of COTA in mucinous ovarian tumors].
    Shi ZL
    Zhonghua Zhong Liu Za Zhi; 1989 May; 11(3):191-2. PubMed ID: 2612330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.